Saturday, August 19, 2023
SK Biopharmaceuticals has entered into strategic and licencing agreements with Hikma to expand its presence into the Middle East and North Africa (MENA) region.
The agreement between SK Biopharmaceuticals and Hikma provides Hikma with exclusive rights to commercialise cenobamate, a drug developed by SK Biopharmaceuticals, in the Middle East and North Africa (MENA) region.
This exclusive commercialisation right extends to some of the most significant countries in the region, including Saudi Arabia, Egypt, and Algeria. This collaboration follows SK Biopharmaceuticals' efforts to expand its reach globally, as they have already ventured into North America, Northeast Asia, and Latin America to enhance patient access to cenobamate on a worldwide scale.
The partnership with Hikma is another step towards achieving these goals, and it signifies SK Biopharmaceuticals' dedication to expanding their market presence and making their innovative medications available to patients in regions where there is a significant medical need.
